Friday 25 June 2021 | 10:00 am – 11:30 am EST
This Symposium will discuss how the issues of selective publishing and closing of data gaps in toxicology might be addresses.
The first presentation is about obstacles that publication bias presents to systematic reviews (SRs), using as a case-study a recent EBTC SR of drug-induced liver injury, where large amounts of relevant evidence were inaccessible due to selective publishing practices:
Link to paper: https://doi.org/10.1038/s41598-021-85708-2
The second presentation is about gaps in data submitted for regulatory approval, focusing on improving access to drug safety and efficacy data currently held back from public view as proprietary.
The third presentation is about methods for understanding the toxicity of chemicals for which there is simply very little data. The importance of transparency in AI-powered, read-across computational tools is discussed.
Three 20-minute presentations will be followed by a panel discussion, where the speakers will answer questions from the audience.
** Agenda **
1. Introduction to EBTC
2. “Evidence-based assessment of three lines of evidence on drug-induced liver injury: main conclusions, limitations and barriers to implementation”. Dr. Katya Tsaioun, EBTC
3. “Gaps in preclinical and clinical data: a need for transparency in the regulatory evidence base”. Dr Jan Turner, Safer Medicines Trust
4. “AI-based data extraction and predictive toxicology – learning from use for chemical safety” Dr. Thomas Hartung, CAAT at Johns Hopkins School of Public Health